3SBio Inc. announced that it has entered into an exclusive licensing deal with Alteogen Inc. for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2) gene pathway for cancer in Mainland China, Hong Kong and Macau. The deal included upfront, milestone and royalty payments. This is the company's first business collaboration with Alteogen.